Supporting Information for

Selective chemical functionalization at N°-methyladenosine residues in DNA enabled by visible-light-mediated photoredox catalysis.

Manuel Nappi, † Alexandre Hofer, † Shankar Balasubramanian* and Matthew J. Gaunt*

Correspondence to: mjg32@cam.ac.uk & sb10031@cam.ac.uk

This PDF file includes:

Materials and Methods
Supplementary Text and Figures
Figs. S1 to S34
Tables S1 and S2
Table of Contents

Materials and Methods

General Remarks 3
General procedures 4

Supplementary Text and Figures

Important remarks on the photocatalyst used 8
Reactions with quinuclidine and quinuclidine derivatives 9
LCMS studies on the formation of the N-hydroxyformamidine product 13
Selective functionalization of N₆mdA ODN 5 with derived 3-nitropyridines 16
LCMS traces of functionalization of N₆mdA ODN 5 and control reaction with unmethylated ODN 7 using different alkyne-derived 3-nitropyridines 18
Comparison of photoredox reaction outcome with [Ru(bpz)₃](PF₆) and [Ru(phen)₃]Cl₂ 26
HRMS studies on [Ru(phen)₃]Cl₂ system and photoredox selectivity 27
HRMS studies on unselective incorporation of intact 3-nitropyridine 1b at dG residues 29
Collection of evidences for the characterisation of N-hydroxyformamidine products 30
Reactions and LC-MS traces for sequences 5b, 5c, 5d and 5e 33
Optimization of ‘click’ Huisgen cycloaddition on alkyne-functionalized N₆mdA ODN 1 37
LCMS traces of functionalization of N₆mdA ODN 5 with alkyne-derived 3-nitropyridines and subsequent Huisgen cycloaddition 39
Enrichment studies of 12/13nt ssDNA 43
Enrichment studies of 99nt ssDNA 45
Enrichment studies of 99bp dsDNA 47

Synthesis of compounds and oligodeoxynucleotides

Synthesis and characterization of derivatives of quinuclidine and 3-nitropyridine 49
Enzymatic synthesis of N₆mdA-containing dsDNA 56

NMR spectra of synthesized compounds 57
**Materials and Methods**

**General Remarks**

Proton nuclear magnetic resonance (1H NMR) spectra were recorded at ambient temperature on a 400 MHz Bruker Avance III HD spectrometer (400 MHz) or a 500 MHz Bruker Avance III HD Smart Probe spectrometer (500 MHz). Chemical shifts (δ) were reported in ppm and quoted to the nearest 0.01 ppm relative to the residual protons in CDCl3 (7.26 ppm), DMSO-d6 (2.50 ppm), methanol-d4 (3.31 ppm) and coupling constants (J) were quoted in Hertz (Hz). Coupling constants were quoted to the nearest 0.1 Hz and multiplicity reported according to the following convention: s = singlet, d = doublet, t = triplet, q = quartet, qnt = quintet, sext = sextet, sept = septet, oct = octet, m = multiplet, br = broad and associated combinations, e.g. dd = doublet of doublets. Where coincident coupling constants have been observed, the apparent (app) multiplicity of the proton resonance has been reported. Data were reported as follows: chemical shift (multiplicity, coupling constants, number of protons and molecular assignment).

Carbon nuclear magnetic resonance (13C NMR) spectra were recorded at ambient temperature on a 400 MHz Bruker Avance III HD spectrometer (101 MHz) or a 500 MHz Bruker Avance III HD Smart Probe spectrometer (126 MHz). Chemical shifts (δ) were reported in ppm and quoted to the nearest 0.1 ppm relative to the residual solvent peaks in CDCl3 (77.16 ppm), DMSO-d6 (39.52 ppm), and methanol-d4 (49.00 ppm). DEPT135, NOE experiments and 2-dimensional experiments (COSY, HMBC and HSQC) were used to support assignments when appropriate but were not included herein.

LCMS spectra were recorded on an Amazon X ESI-MS (Bruker) connected to an Ultimate 3000 LC (Dionex). Oligodeoxyribonucleotides were analysed using a gradient of 5-30% or 5-40% methanol vs. an aqueous solution of 10 mM triethylamine and 100 mM hexafluoro-2-propanol on a XTerra MS C18 column (125Å, 2.5 μm, 2.1x50mm) with TMS endcapping or an XBridge Oligonucleotide BEH C18 column (130Å, 2.5 μm, 2.1x50mm). Small molecules were analysed with a gradient of 0-100% acetonitrile with 0.1% formic acid vs. water with 0.1% formic acid on a Kinetex® C18 column (100 Å, 2.6 μm, 50 x 2.1 mm). Mass chromatograms shown are base peak chromatograms, UV absorption was recorded at 260 nm.

High-resolution mass spectra (HRMS) of small molecules were conducted using Shimadzu LC-MS 9030 QToF. Oligodeoxyribonucleotides were analysed using a gradient of 5-30% methanol vs. an aqueous solution of 10 mM triethylamine and 100 mM hexafluoro-2-propanol on a XTerra MS C18 column (125Å, 2.5 μm, 2.1x50mm) with TMS endcapping. Small molecules were analysed with a gradient of 0-100% acetonitrile with 0.1% formic acid vs. water with 0.1% formic acid on a Kinetex® C18 column (100 Å, 2.6 μm, 50 x 2.1 mm).

Analytical thin layer chromatography (TLC) was performed using pre-coated Merck glass-backed silica gel plates (Silicagel 60 F254 0.2 mm). Visualization was achieved using ultraviolet light (254 nm) and chemical staining with basic potassium permanganate solution as appropriate. Flash column chromatography was undertaken on Fluka or Material Harvest silica gel (230-400 mesh) under a positive pressure of air or on a CombiFlash Rf 200 (Teledyne Isco) system using 50 μm Si-HP PuriFlash columns.
Primer elongation reactions were performed on a T100 Thermocycler (BioRad) or on a 96 Universal Gradient (PeqStar) machine.

Automated gel electrophoresis was performed using an Agilent Technologies 2200 Tapestation and D1000 ScreenTapes and sample buffer.

qPCR was performed using a CFX96 Real-TimeSystem (BioRad), and data was processed using CFX software manager 3.1(BioRad). qPCR reactions (volume: 10 μL) contained DNA calibration or sample mixtures (1 μL), the corresponding forward and reverse primers (1 μM each), and Brilliant III ultra-Fast SYBR green qPCR mastermix (Agilent Technologies, 5 μL). Reactions were run according to the manufacturer’s protocol. Calibration curves were made to determine the amounts of target DNA in the analysed samples.

Oligodeoxyribonucleotides (ODNs), including short ONDs for reactions, 99nt ssDNA strands and template and primers for the synthesis of 99nt dsDNA strands were custom synthesised and HPLC-purified by ATDBio or Sigma-Aldrich and used without further purification after dissolution into milliQ H₂O.

Reagents were obtained from Sigma-Aldrich, Acros, Alfa Aesar, TCI, or Jena Bioscience and used without further purification. Enzyme solutions were obtained from Zymo, New England BioLabs, and Sigma and used directly.

Dichloromethane, ethyl acetate, tetrahydrofuran, toluene, and petroleum ether (40–60) were dried and distilled using standard methods. Water was purified on a milliQ system. Other solvents used were purchased anhydrous and used without further purification unless otherwise stated.

Reactions were carried out under nitrogen atmosphere unless otherwise stated. Reactions were monitored by LCMS.

General procedures

General procedure A: functionalization of N⁶mdA in short ODNs with quinuclidine and derivatives

A 2 mL microwave vial was charged with a solution containing the ODN substrate (200 μM in milliQ H₂O, 12.5 μL). In a separate Eppendorf tube, the appropriate amount of quinuclidine or its derivative was dissolved using a stock solution of [Ru(bpz)₃](PF₆)₂ (2 mg in 1 mL of 20% MeCN in milliQ H₂O, 2.3 mM, 12.5 μL) or [Ru(phen)₃]Cl₂ (2 mM in 20% MeCN in milliQ H₂O, 12.5 μL). The latter mixture was then added to the ODN solution and the microwave vial was sealed under nitrogen atmosphere after flushing for 15-20 seconds. The vial was then placed at 5 cm from a 15 W CFL bulb. The reaction was irradiated for 5 hours, diluted with milliQ H₂O (25 μL) and filtered through a prewashed Mini Quick Spin Oligo Column (Roche). The obtained mixture was analyzed directly by LCMS.
**General procedure B: functionalization of N₆mdA in short ODNs with 3-nitropyridine and derivatives**

A 2 mL microwave vial was charged with a solution containing the ODN substrate (200 µM in milliQ H₂O, 12.5 µL). In a separate Eppendorf tube, quinuclidine (5.5 mg, 50 µmmol) and the appropriate amount of 3-nitropyridine or respective derivatives were dissolved using a stock solution of [Ru(bpz)₃](PF₆)₂ (2 mg in 1 mL of 20% MeCN in milliQ H₂O, 2.31 mM, 12.5 µL) or Ru(Phen)₃Cl₂ (1.5 mg in 1 mL of 20% MeCN in milliQ H₂O, 2.1 mM, 12.5 µL). The latter mixture was then added to the oligo solution and the microwave vial was sealed under nitrogen atmosphere, flushing for 15-20 seconds. The vial was then placed in a distilled-water bath at approximately 1 cm from a 15 W CFL or 55 W CFL bulb or inside a 55W CFL bulb, in which case a fan was used for temperature control. The reaction was irradiated for 10 min (if not stated otherwise), diluted with water (25 µL) and filtered through a prewashed Mini Quick Spin Oligo Column (Roche). The obtained mixture was analyzed directly by LCMS.

**General procedure C: click reaction on the functionalized N₆mdA in short ODNs**

To the resulting ODN mixture from general procedure B (25 µL) in a 1.5 ml Eppendorf tube was added quinuclidine (5.5 mg, 50 µmol, dissolved in 10 µL of milliQ H₂O), azide-PEG₃-biotin conjugate (20 mM, 5 µL), sodium ascorbate (40 mM, 5 µL) and CuSO₄ (2 mM, 5 µL). Final concentrations: quinuclidine 1 M, azide-PEG₃-biotin conjugate: 2 mM, sodium ascorbate: 4 mM, CuSO₄ 0.2 mM. After 30 min reaction at room temperature, the reaction was filtered through a prewashed Mini Quick Spin Oligo Column (Roche). The obtained mixture was analyzed directly by LCMS.

**General procedure D: enrichment of short N₆mdA ODNs with streptavidin magnetic beads**

To the resulting ODN mixture from general procedure C in a 1.5 ml Eppendorf DNA LoBind microcentrifuge tube was added 5X adapted binding buffer (40 µL; 25 mM Tris, 2.5 mM EDTA, 5 M NaCl, pH 8.5, 0.25% Tween 20) and milliQ H₂O (for a final volume of 200 µL). Streptavidin MagneSphere® Paramagnetic Particles (300 µL of a 1 mg/ml suspension) were suspended in a 1.5 ml Eppendorf DNA LoBind microcentrifuge tube, separated from the storage buffer on a magnetic stand, washed twice with 0.5X SSC buffer (200 µL; 75 mM NaCl, 7.5 mM sodium citrate, pH 7.2) and once with 1X adapted binding buffer (200 µL; 5 mM Tris, 0.5 mM EDTA, 1 M NaCl, pH 8.5, 0.05% Tween 20). The oligo solution (200 µL) was added to the paramagnetic particles and after 10 minutes incubation at r.t. the supernatant was collected for LCMS analysis. The beads were carefully washed with 1X adapted binding buffer (3x 200 µL), then transferred into a new microcentrifuge tube with 200 ul adapted binding buffer and washed another time with adapted binding buffer (1x 200 µL). They were then incubated in 100 mM NaOH (3x 10 min at r.t. with 200 µL), and finally washed again with adapted binding buffer (3x 200 µL). Elution of the retained oligonucleotides was performed by incubation with 10% aqueous hydrazine (25 µL) for 5 min at r.t. followed by an additional wash with water (25 µL). Both fractions of 25 µL were combined, filtered through a prewashed Mini Quick Spin Oligo Column (Roche) and analyzed directly by LCMS.
**General procedure E: functionalization of N°mdA in 99nt ssDNA with the 3-nitropyridine probe for enrichment**

A 2 mL microwave vial was charged with a mixture of two ODN substrates (methylated and unmethylated, 2 μM in milliQ H2O, 12.5 μL each). In a separate Eppendorf tube, quinuclidine (8.25 mg, 75 μmol) and the 3-nitropyridine probe (0.3 mg, 1.3 μmol) were dissolved using a stock solution of [Ru(phen)3]Cl2 (3 mM in 1 mL of 30% MeCN in milliQ H2O, 12.5 μL). The latter mixture was then added to the ODN mixture. For the reactions with added salmon sperm DNA, 2 ul of a salmon sperm ssDNA solution (5 mg/ml, abcam ab229278) were added before the photoredox reaction. Final concentrations: ODNs: 0.67 μM each, quinuclidine: 2 M, 3-nitropyridine probe: 33 mM, [Ru(phen)3]Cl2: 1 mM, 10 % MeCN in H2O. The microwave vial was sealed under nitrogen atmosphere after flushing for 15-20 seconds. The vial was then placed inside a 55W CFL bulb. The mixture was irradiated for 5 min while the temperature was maintained with a fan and subsequently filtered through a prewashed Micro BioSpin 6 column (BioRad) after the reaction.

**General procedure F: click reaction on the functionalized N°mdA in 99nt ssDNA**

To the resulting ODN mixture from general procedure E in a 1.5 ml Eppendorf tube was added quinuclidine (8.25 mg, 75 μmole in 10 μL H2O), Azide-PEG3-biotin conjugate (20 mM, 7.5 μL), sodium ascorbate (40 mM, 7.5 μL) and CuSO4 (2 mM, 7.5 μL). Final concentrations: quinuclidine: 1 M, Azide-PEG3-biotin conjugate: 2 mM, sodium ascorbate: 4 mM, CuSO4 0.2 mM. After 30 minutes reaction at r.t., the mixture was filtered twice through a prewashed Micro BioSpin 6 column (BioRad).

**General procedure G: functionalization of N°mdA in 99bp dsDNA with the 3-nitropyridine probe for enrichment**

A 2 mL microwave vial was charged with a mixture of two dsODN substrates (methylated and unmethylated, 0.25-0.35 μM in milliQ H2O, 8.3 μL each). In a separate Eppendorf tube, quinuclidine (5.5 mg, 50 μmol) and the 3-nitropyridine probe (0.2 mg) were dissolved using a stock solution of [Ru(phen)3]Cl2 (3 mM in 1 mL of 30% MeCN in milliQ H2O, 8.3 μL). The latter mixture was then added to the ODN mixture. For the reactions with added salmon sperm DNA, 2 ul of a salmon sperm ssDNA solution (5 mg/ml, abcam ab229278) were added before the photoredox reaction. Final concentrations: ODNs: 0.08-0.12 μM each, quinuclidine: 2 M, 3-nitropyridine probe: 33 mM, [Ru(phen)3]Cl2: 1 mM, 10 % MeCN in H2O. The microwave vial was sealed under nitrogen atmosphere after flushing for 15-20 seconds. The vial was then placed inside a 55W CFL bulb. The mixture was irradiated for 5 min while the temperature was maintained with a fan and subsequently filtered through a prewashed Micro BioSpin 6 column (BioRad) after the reaction.

**General procedure H: click reaction on the functionalized N°mdA in 99bp dsDNA**

To the resulting ODN mixture from general procedure G in a 1.5 ml Eppendorf tube was added quinuclidine (5.5 mg, 50 μmol in 5 μL H2O), Azide-PEG3-biotin conjugate (20 mM, 7.5 μL),
sodium ascorbate (40 mM, 7.5 µL) and CuSO₄ (2 mM, 7.5 µL). Final concentrations: quinuclidine: 1 M, Azide-PEG₃-biotin conjugate: 2 mM, sodium ascorbate: 4 mM, CuSO₄ 0.2 mM. After 30 minutes incubation at r.t., the reaction was filtered twice through a prewashed Micro BioSpin 6 column (BioRad).

General procedure I: enrichment of N⁶mdA 99nt ssDNA and dsDNA ODNs with streptavidin magnetic beads

To the resulting ODN mixture from general procedures F and H (75 or 50 µL) in a 1.5 ml Eppendorf DNA LoBind microcentrifuge tube was added 5X adapted binding buffer (40 µL; 25 mM Tris, 2.5 mM EDTA, 5 M NaCl, pH 8.5, 0.25% Tween 20), poly[dl:dC] (5 µL; 5 µg/µl), and water (80 or 105 µL, to a total volume of 200 µL). Streptavidin MagneSphere® Paramagnetic Particles (100 µL of a 1 mg/ml suspension) were separated from the storage buffer on a magnetic stand, washed twice with 0.5X SSC buffer (200 µL; 75 mM NaCl, 7.5 mM sodium citrate, pH 7.2) and once with 1X adapted binding buffer (200 µL; 5 mM Tris, 0.5 mM EDTA, 1 M NaCl, pH 8.5, 0.05% Tween 20) with poly[dl:dC] (5 µL; 5 µg/µl). The oligo solution (200 µL) was added to the prewashed paramagnetic particles and after 10 minutes incubation at r.t. the supernatant was collected for the quantification of both ODN sequences by qPCR. The beads were washed three times with 1X adapted binding buffer (3x 200 µL), then transferred into a new microcentrifuge tube with 200 ul adapted binding buffer and washed another time with adapted binding buffer (200 µL). They were then incubated in 100 mM NaOH at r.t. for 10 min three times (3x 200 µL), and finally washed again three times with adapted binding buffer (3x 200 µL). Elution of the bound oligonucleotides was performed by incubation with 10% aqueous hydrazine (25 µL) at r.t. for 5 min. After an additional wash of the paramagnetic particles with water (25 µL), both fractions were combined, purified using Zymo Oligo Clean & Concentrator™ spin columns (according to the manufacturers protocol) and the oligonucleotides eluted with 15 µL milliQ water. 7.5 µL of this purified fraction was kept for the determination of enrichment factors by quantifying both ODN sequences by qPCR. The other 7.5 µL were diluted with 5X adapted binding buffer (10 µL) and water (32.5 µL) and treated with prewashed Streptavidin MagneSphere® Paramagnetic Particles (100 µL of a 1 mg/ml suspension) to remove any residue of unselectively biotinylated oligonucleotides. The supernatant was purified using Zymo Oligo Clean & Concentrator™ spin columns according to the manufacturers protocol and the oligonucleotides eluted with 15 µL milliQ water. The enrichment factor was determined by quantifying both ODN sequences by qPCR.
Supplementary Text and Figures

Important remarks on the photocatalyst used

While the design plan in Figure 2 of the main manuscript describes the use of Ru(phen)$_3$Cl$_2$ photocatalyst and its oxidative quenching cycle, many of the preliminary results of this project were conducted using similar photocatalyst, [Ru(bpz)$_3$](PF$_6$)$_2$. Due to the difference in the reduction potentials, the operative photoredox cycle for the latter is more likely to be the reductive quenching cycle: oxidation of the quinuclidine 3 as first step and reduction of 3-nitropyridine 1a to restore the metal complex ground state (Fig. S1). It is important to note that while the photoredox cycles are different, the radical species formed are the same (int I and int III); indeed, both the photocatalysts showed very similar yields and reaction profile on short DNA fragments. However, the difference in the quenching cycle was crucial for the application of the reaction to single stranded (ss) and double stranded (ds) long oligonucleotides, as the Ru(phen)$_3$Cl$_2$ showed significantly cleaner reaction profiles due to lower oxidative power compare to [Ru(bpz)$_3$](PF$_6$)$_2$ (Fig. S16).

Fig. S1. Proposed photoredox quenching cycles for [Ru(bpz)$_3$](PF$_6$)$_2$ and Ru(phen)$_3$Cl$_2$. 
Reactions with quinuclidine and quinuclidine derivatives

**Reaction with quinuclidine on methylated/unmethylated ODNs**

Initial studies demonstrated that irradiation of a mixture of ODN 5 with quinuclidine 3 and the photosensitiser [Ru(bpz)$_3$]$_2$[(PF$_6$)$_2$] resulted in the formation of two products as detected by LCMS (Fig. S2). Whereas retention time and MS profile of the first product clearly indicated that it is the demethylation product [dA] 7, the other product had the mass of a putative quinuclidine derivative [N$_6$mdA-Q].

![Reaction Scheme](image)

**Fig. S2.** Reaction scheme for the selective N$_6$mdA functionalization reaction on the methylated ODN 5, LCMS traces of the reaction mixture after the reaction (top: base peak mass chromatogram, middle: UV$_{260}$ chromatogram) and of the starting material (UV$_{260}$ chromatogram; bottom), and extracted mass spectrum of the [N$_6$mdA-Q] peak.
When substituting substrate ODN 5 by its demethylated analogue 7 and applying the same conditions, no reaction could be observed (Fig. S3).

CTTGACAG[dA]CTAG
100 µM (2.5 nmol), 7
[M-3H]⁻ = 1318

Fig. S3. Reaction scheme for the application of the N⁶mdA-selective functionalization conditions using quinuclidine 3 on the unmethylated ODN 7, LCMS traces of the reaction mixture after the reaction (UV 260 chromatogram; top) and of the starting material (UV 260 chromatogram; bottom), and extracted mass spectrum of the [dA] peak (ODN 7) after reaction.

This set of experiments led to the conclusion that both observed products in the reaction on ODN 5 are the result of a selective reaction at the N⁶mdA residue. We posit that both are the product of an initial highly selective HAT from the N-methyl group to the well-described quinuclidinium radical cation formed in situ.
**Reaction with quinuclidine derivative 2-(quinuclidin-3-yl)propan-2-ol**

Further confirmation of the incorporation of quinuclidine on the N^6mdA residue was shown by developing a quinuclidine derivative that is compatible with the reaction in Fig. S2: 2-(Quinuclidin-3-yl)propan-2-ol. Under similar conditions to the quinuclidine functionalization in Fig. S2, we observed the new product [N^6mdA-Qder] along with product 7 (Fig. S4).

![Chemical structure](image)

**Fig. S4.** Reaction scheme for the selective N^6mdA functionalization reaction with a developed quinuclidine derivative on methylated ODN 5; LCMS traces of the reaction mixture after the reaction (top: base peak mass chromatogram, middle: UV_{260} chromatogram) and of the starting material (UV_{260} chromatogram; bottom), and extracted mass spectrum of the [N^6mdA-Qder] peak.

This experiment confirms that the second observed product (as shown in Fig. S4) is a quinuclidine derivative.
Reactions with $[\text{Ru(bpz)}_3](\text{PF}_6)_2$ and reduced concentrations of quinuclidine

To understand if excited $[\text{Ru(bpz)}_3](\text{PF}_6)_2$ can damage ODNs in the absence of high amounts of quinuclidine, we run control reaction on ODN 5 (as depicted in the scheme of Fig. S2) with decreasing concentrations of quinuclidine 3 (Fig. S5).

![LCMS UV traces](image)

**Fig. S5.** LCMS UV$_{260}$ traces of the reaction mixture after reaction (according to General Procedure A) with different concentrations of quinuclidine 1. **A:** 2.0 M quinuclidine. **B:** 0.2 M quinuclidine. **C:** 0.02 M quinuclidine. Considerable broadening of the LCMS peaks in the lower chromatograms indicates decomposition of the ODNs at reduced concentrations of quinuclidine.

Considerable broadening of the LCMS peaks when using lower quinuclidine concentrations indicates that decreasing quinuclidine concentration is detrimental to the selectivity of the reaction.
LCMS studies on the formation of the N-hydroxyformamidine product

Encouraged by the validation of the HAT step, we next investigated the in situ generation of the nitrosoarene spin trapping reagent 2a from 3-nitropyridine 1a and its interception of the N₆mdA-derived α-amino radical. We found that irradiation of a solution of oligonucleotide 5, quinuclidine 3, [Ru(bpz)₃](PF₆)₂ and 3-nitropyridine 1a for 10 minutes at room temperature produced N-hydroxyformamidine conjugate [N₆mdA-P] 6 in 14% yield (Fig. S6), along with quinuclidine product [N₆mdA-Q] (3% yield) and demethylation product [dA] 7 (26% yield).

Fig. S6. Reaction scheme for the selective N₆mdA functionalization reaction on methylated ODN 5 in the presence of 3-nitropyridine (1a); detection of the new N-hydroxyformamidine product [N₆mdA-P] 6 (in 14% assay yield) with m/z 1358. LCMS traces show the reaction mixture after the reaction (top: base peak mass chromatogram, middle: UV₂₆₀ chromatogram) and the starting material (UV₂₆₀ chromatogram; bottom). The MS shows the extracted mass spectrum of the [N₆mdA-P] 6 peak.
Given the fact that the observed mass of N-hydroxyformamidine conjugate [N^6mdA-P] 6 (m/z = 1358) is very similar to the mass of quinuclidine product [N^6mdA-Q] (m/z = 1359), we conducted a control experiment using 5-Phenyl-3-nitropyridine (Fig. S7) to confirm that the new product 6 is indeed a derivative of 3-nitropyridine 1a and not the oxidized version of quinuclidine product 6. When 5-phenyl-3-nitropyridine was used under similar reaction conditions, we observed the formation of a new product [N^6mdA-P-Ph] with m/z = 1384 in 5% yield, quinuclidine product [N^6mdA-Q] (2% yield) and demethylated adduct [dA] 7 (15% yield). The mass of the new product [N^6mdA-P-Ph] clearly reflects the incorporation of 5-Phenyl-3-nitropyridine and, together with the fact that no peak with m/z = 1358 was detected, it unambiguously confirms that product [N^6mdA-P] 6 is indeed a 3-nitropyridine 1a derivative.

Fig. S7. N^6mdA-selective functionalization of N^6mdA ODN 5 with quinuclidine 1 and 2-phenyl-3-nitropyridine resulted in a product with m/z 1384 that corresponds to incorporation of a 2-phenyl-3-nitropyridine moiety [N^6mdA-P-Ph] along with the previously described quinuclidine product [N^6mdA-Q]. LCMS traces show the reaction mixture after the reaction (top: base peak mass chromatogram, middle: UV[260] chromatogram) and the starting material (UV[260] chromatogram; bottom). The MS shows the extracted mass spectrum of the [N^6mdA-P-Ph] product peak.
Additional evidences are provided by the following experiment, where we used 3-nitropyridine 1a and 2-(Quinuclidin-3-yl)propan-2-ol instead of quinuclidine 3 (Fig. S8). In this case, we could detect the formation of product \([N^6\text{mdA}-P]\) 6 with \(m/z = 1358\) (5% yield) and the 2-(Quinuclidin-3-yl)propan-2-ol product \([N^6\text{mdA}-\text{Qder}]\), but we could not observe the formation of the previously observed quinuclidine product \([N^6\text{mdA}-\text{Q}]\) as expected. This experiment clearly confirms that product \([N^6\text{mdA}-P]\) 6 is not the mere oxidized version of quinuclidine product.

**Fig. S8.** \(N^6\text{mdA}\)-selective functionalization of \(N^6\text{mdA}\) ODN 5 with the quinuclidine derivative 2-(quinuclidin-3-yl)propan-2-ol and 3-nitropyridine (2a) resulted in the product with \(m/z 1358\) that corresponds to incorporation of a 3-nitrosopyridine moiety \([N^6\text{mdA}-P]\) 6 along with the product with the derivatized quinuclidine \([N^6\text{mdA}-\text{Qder}]\). LCMS traces show the reaction mixture after the reaction (top: base peak mass chromatogram, middle: UV\(_{260}\) chromatogram) and the starting material (UV\(_{260}\) chromatogram; bottom). The MS shows the extracted mass spectrum of the \([N^6\text{mdA}-\text{Qder}]\) product peak as well as of the \([N^6\text{mdA}-P]\) 6 product region (insert).
Selective functionalization of $N^6$mdA ODN 5 with derived 3-nitropyridines

Various 3-nitropyridine derivatives have been tested under the $N^6$mdA selective reaction conditions described in Fig. S6. The aim of this study was to provide information regarding the solubility, reactivity and compatibility of modified 3-nitropyridine compounds toward the development of a probe that can contain an alkyne group for future enrichment studies.

Table S1. Conditions and yields for the selective functionalization reactions of $N^6$mdA ODN 5 with different 3-nitropyridine derivatives.

| 3-nitropyridine der. | [c] | reaction time<sup>a</sup> | yield $[N^6$mdA-PX]<sup>b</sup> (m/z [M-3H]<sup>3-</sup>) | yield $[^d]A$<sup>c</sup> | yield $[N^6$mdA-Q]<sup>b</sup> |
|---------------------|-----|------------------------|---------------------------------|-----------------|-----------------|
| ![Chemical structure](image) | 0.4 M | 1 h 15 W CFL | 5 % (1384) | 15 % | 2 % |
| ![Chemical structure](image) | 0.4 M | 1 h 15 W CFL | 7 % (1384) | 17 % | 2 % |
| ![Chemical structure](image) | 0.4 M | 10 min 15 W CFL | 4 % (1385) | 38 % | 3 % |
| ![Chemical structure](image) | 0.2 M | 1 h 15 W CFL | 2 % (1420) | 11 % | 3 % |
| ![Chemical structure](image) | 0.13 M | 1 h 15 W CFL | 1 % (1420) | 19 % | 2 % |
| ![Chemical structure](image) | 0.13 M | 1 h 15 W CFL | 2 % (1420) | 13 % | 2 % |
| derived 3-nitropyridine | [c] | reaction time<sup>a</sup> | yield [N<sup>6</sup>mdA-PX]<sup>b</sup> (m/z [M-3H])<sup>b</sup> | yield [dA]<sup>b</sup> | yield [N<sup>6</sup>mdA-Q]<sup>b</sup> |
|------------------------|-----|-------------------|------------------------|----------------|----------------|
| ![Image](image1.png) 0.08 M | 1 h 15 W CFL | 3 % (1420) | 28 % | 2 % |
| ![Image](image2.png) 0.1 M | 20 min 15 W CFL | 7 % (1394) | 35 % | 1 % |
| ![Image](image3.png) 1b 0.1 M | 20 min 15 W CFL | 8 % (1394) | 17 % | 5 % |
| ![Image](image4.png) 1b 0.1 M | 20 min 60 W CFL | 17 % (1394) | 37 % | 2 % |
| ![Image](image5.png) 0.1 M | 20 min 15 W CFL | 8 %<sup>c</sup> (1385) | 25 % | 2 %<sup>c</sup> |

<sup>a</sup>other reaction conditions according to General Procedure B  
<sup>b</sup> assay yields by LCMS  
<sup>c</sup>species coeluting in LCMS, approximate yields according to MS signal intensities

We first started our exploration using 3-nitropyridine derivatives containing a phenyl group as substituent or linker for the alkyne moiety. The choice of the phenyl group was done based on the small changes in the reduction potential compare to unsubstituted 3-nitropyridine. Indeed, 3-nitropyridine needs to be reduced to generate the desired spin trapping reagent 3-nitrosopyridine; therefore, a phenyl substituent would not compromise the key reduction step. Unfortunately, all the substrates containing an aromatic substituent were poorly soluble in the aqueous media and showed low yields for the selective functionalization of N<sup>6</sup>mdA. Later, we found that the amide linkage was well tolerated in position 4 and 5 of the 3-nitropyridine, furnishing the desired functionalisation in better yields. Finally, we could improve the initial result of 3-nitropyridine 1b (8% yield) using a more powerful source of light, such as 60W CFL (17% yield).
LCMS traces of functionalization of N<sup>6</sup>mdA ODN 5 and control reaction with unmethylated ODN 7 using different alkyne-derived 3-nitropyridines

This is a collection of LC traces of the selective photoredox reactions on N<sup>6</sup>mdA containing ODN 5 described in Table S1 using different 3-nitropyridine alkyne derivatives (probes) and the corresponding control experiments on unmethylated ODN 7 under the same reaction conditions. For each probe, the first chromatogram is the MS-trace of the reaction on [N<sup>6</sup>mdA] ODN 5. The second chromatogram shows the UV-trace of the same reaction. The third and the fourth chromatograms represent respectively the MS and UV-traces of the control experiment on unmethylated [dA] ODN 7. Finally, the last trace is the MS spectra of the new product peak observed in the first two traces.

While the formation of a new product is evident for all the probes tested on [N<sup>6</sup>mdA] ODN 5, control experiments showed clean recovery of unmethylated [dA] ODN 7 in all cases, without the presence of any N-hydroxyformamidine adducts. These results not only indicate an exquisite selectivity for the functionalisation of N<sup>6</sup>mdA, but also unambiguously confirm the position of the new label on the N<sup>6</sup> methyl group.
Fig. S9. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with N-(3-(5-nitropyridin-2-yl)phenyl)hex-5-ynamide on N^6-mdA ODN 5 (top; base peak MS chromatogram and UV\textsubscript{260} chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV\textsubscript{260} chromatogram). The MS shows the extracted mass spectrum of the [N^6-mdA-PX] peak.
Fig. S10. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with N-(3-(5-nitropyridin-2-yl)phenyl)hex-5-ynamide on N₆mdA ODN 5 (top; base peak MS chromatogram and UV₂₆₀ chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV₂₆₀ chromatogram). The MS shows the extracted mass spectrum of the [N₆mdA-PX] peak.

\[\text{reaction with } [\text{N₆mdA}]\]
\[\text{oligonucleotide}\]

\[\text{[N₆mdA]}\]
\[\text{[dA]}\]
\[\text{[N₆mdA-PX]}\]

\[\text{reaction with } [\text{dA}]\]
\[\text{oligonucleotide}\]

\[\text{[dA]}\]

\[\text{[dA]}\]
\[\text{[N₆mdA]}\]
\[\text{[N₆mdA-PX]}\]
Fig. S11. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with N-(3-(3-nitropyridin-4-yl)phenyl)hex-5-ynamide on N^6 mdA ODN 5 (top; base peak MS chromatogram and UV260 chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV260 chromatogram). The MS shows the extracted mass spectrum of the [N^6 mdA-PX] peak.
3-(3-nitropyridin-4-yl)-N-(pent-4-yn-1-yl)benzamide

Fig. S12. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with 3-(3-nitropyridin-4-yl)-N-(pent-4-yn-1-yl)benzamide on N⁶mdA ODN 5 (top; base peak MS chromatogram and UV260 chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV260 chromatogram). The MS shows the extracted mass spectrum of the [N⁶mdA-PX] peak.
5-nitro-N-(pent-4-yn-1-yl)picolinamide

Fig. S13. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with 5-nitro-N-(pent-4-yn-1-yl)picolinamide on N6mdA ODN 5 (top; base peak MS chromatogram and UV260 chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV260 chromatogram). The MS shows the extracted mass spectrum of the [N6mdA-PX] peak.
**N-(5-nitropyridin-3-yl)hex-5-ynamide, 1b**

Fig. S14. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with 5-nitro-N-(pent-4-yn-1-yl)picolinamide on N<sup>6</sup>mdA ODN 5 (top; base peak MS chromatogram and UV<sub>260</sub> chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV<sub>260</sub> chromatogram). The MS shows the extracted mass spectrum of the [N<sup>6</sup>mdA-PX] ODN 9 peak. * denotes non-ODN signals probably arising from 5-nitro-N-(pent-4-yn-1-yl)picolinamide-derived species that were not completely removed by size-exclusion filtration.
Fig. S15. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with 5-nitro-N-(pent-4-yn-1-yl)picolinamide on N<sup>6</sup>mdA ODN 5 (top; base peak MS chromatogram and UV<sub>260</sub> chromatogram) and unmethylated ODN 7 (bottom; base peak MS chromatogram and UV<sub>260</sub> chromatogram). The MS shows the extracted mass spectrum of the [N<sup>6</sup>mdA-PX] peak.
Comparison of photoredox reaction outcome with [Ru(bpz)₃](PF₆)₂ and [Ru(phen)₃]Cl₂

Based on the proposed reaction mechanism described in Fig. 2 of the main text, excited [Ru(bpz)₃](PF₆)₂ undergoes reductive quenching through the oxidation of quinuclidine 3. Instead, excited [Ru(phen)₃]Cl₂ directly reduces the 3-nitropyridine through the oxidative quenching cycle. Even though both photocatalysts are able to promote the desired chemistry, which quenching cycle is operative under the reaction conditions could be important for the stability of the starting oligonucleotide and the selectivity of the process. Below, we compared the UV traces of reactions using either [Ru(bpz)₃](PF₆)₂ or [Ru(phen)₃]Cl₂ in otherwise identical conditions (Fig. S16).

Fig. S16. LCMS traces (UV 260) of the N⁶mdA functionalisation in ODN 5 relying on the reductive quenching pathway of [Ru(bpz)₃](PF₆)₂ (upper trace, yellow) and the oxidative quenching of [Ru(phen)₃]Cl₂ (lower trace, blue). According to the UV traces, the use of [Ru(phen)₃]Cl₂ affords a more selective and clean reaction.

According to the UV traces shown, the use of [Ru(phen)₃]Cl₂ affords a distinctively more selective and clean reaction, indicating that relying on the oxidative quenching pathway for the generation of the 3-nitrosopyridine derivative and quinuclidinium radical cation to functionalise N⁶mdA minimised potential trace side-reactions on the ODN substrate.
HRMS studies on Ru(phen)$_3$Cl$_2$ system and photoredox selectivity

Whereas the LCMS traces of the photoredox reaction with [Ru(bpz)$_3$](PF$_6$)$_2$ indicate the occurrence of trace side reactions, we thoroughly analysed the products of the reaction with [Ru(phen)$_3$]Cl$_2$ by HRMS to confirm identity of the compounds and understand whether any other ‘on-DNA’ N-hydroxyformamidine product was formed (Fig. S17).

![HRMS Trace]

**Fig. S17.** All the products have been characterized by HMRS using a Shimadzu LC-MS (Q-Tof) 9030. Control experiment using the corresponding oligonucleotide without N$^6$mdA did not show any N-hydroxyformamidine adducts, searching for the calculated exact masses within a range of 100 ppm. These results indicate >100:1 selectivity (detection limit: 0.00007%) for the HAT process and addition of the α-amino radical to the nitroso intermediate.
Identity of the demethylation product 7, the quinuclidine derivative $[\text{N}^6\text{mdA-Q}]$, and the N-hydroxyformamidine product 9 were confirmed by HRMS. We further observed metal complexes of the N-hydroxyformamidine products (with Ni(II) and Zn(II)) as confirmed by the observed high-resolution mass and isotope pattern (Fig. S17). Furthermore, in the reaction mixture from a control reaction with unmethylated ODN 7 as substrate under identical conditions, we could not detect any N-hydroxyformamidine product (with a detection limit of 0.00007%), indicating a >100:1 selectivity of the HAT process and the formation of the N-hydroxyformamidine on N$^6$mdA. Moreover, HMRS analysis of the photoredox crude reaction mixture showed a peak with the exact mass of the nitroso intermediate 2b (Pred. $C_{11}H_{11}N_3O_2+H = 218.0924$, found 218.0926), supporting the proposed mechanism.
HRMS studies on unselective incorporation of intact 3-nitropyridine 1b at dG residues

To further understand the selectivity of the developed N⁶mdA functionalisation process, we thoroughly analysed the reaction mixture of the photoredox conjugation (according to the scheme in Fig. S17) by HRMS. The only apparent trace products arising from a non-selective reaction were identified as incorporation of the unmodified 3-nitropyridine probe 1b into the ODN substrate (Fig. S18). No trace of any other side reaction was detected.

![Fig. S18. Non-selective 3-nitropyridine 1b products (red chromatogram, m/z = 1399.92, 1000 ppm range, magnification factor 100). Incorporation of the unmodified probe (not the nitroso derivative, as in the main pathway resulting in N⁶mdA functionalisation) by a different unknown mechanism.](image)

Importantly, HRMS-based comparison of the trace impurities with the N⁶mdA-specific N-hydroxyformamidine formation shows that the overall selectivity for the incorporation of 1b onto N⁶mdA is 98% (50:1).

To understand if the reaction was specific to one of the canonical deoxynucleosides, we applied the conditions on a set of four unmethylated 13nt ODNs with a 4:4:4:1 distribution of the four canonical nucleosides. Whereas for the ODNS containing only one dA, dC, or dT residue, several products were observed (as for ODN 5 in Fig S18), only two new peaks were found for the ODN containing only one dG residue, indicating that the unselective incorporation of 1b is specific to dG (Fig. S19).

![Fig. S19. Non-selective 3-nitropyridine 1b products (red chromatogram, magnification factor 100) of an oligonucleotide that contains only one dG (ATCTACACTGACT). The number of non-selective products decreased in this reaction, suggesting that the trace incorporation of 1b occurs at dG. Interestingly, the chromatogram shows two distinct non-selective products with 3-nitropyridine 1b.](image)

Overall, these studies show that the selectivity of N⁶mdA functionalisation with the 3-nitropyridine 1b versus any other nucleoside is 98% (50:1) and indicate that only dG residues might undergo trace functionalisation, although via a different pathway not resulting in a hydrolysable N-hydroxyformamidine linkage.
Collection of evidences for the characterisation of N-hydroxyformamidine products

**Evidence for the selective functionalisation of the N6mdA residue**

In the proposed mechanism, we envision the abstraction of an H atom from the N6 methyl group of N6mdA to obtain the corresponding α-amino radical species (Fig. 2, main text). To confirm the selective HAT and therefore the position of the new label in the observed products, we conducted several control experiments where oligonucleotide 7 (containing the same sequence of oligonucleotide 5 but having dA instead of N6mdA) was subjected to our photoredox conditions with various 3-nitropyridine alkyne-derivatives 1 (Fig. S20).

![Fig. S20](image)

**Fig. S20.** Control experiments on the unmethylated ODN substrate 7 using different 3-nitropyridine derivatives, confirming that the reaction takes place on the N6 methyl group of N6mdA.

In all cases, LCMS of the reactions showed recovery of pure unreacted oligonucleotide 7, with no products apparent (such as the N-hydroxyformamidine products when the methylated substrate ODN 5 was used, see Fig. S13, S14 and S15). This confirms that no visible reaction takes place on ODNs without N6mdA. **These results not only indicate an exquisite selectivity for the functionalisation of N6mdA, but also unambiguously confirm the position of the new label on the N6 methyl group (HAT selectivity > 100:1).**

**Evidence for the N-hydroxyformamidine structural linkage**

The N-formamidine group follows a distinct hydrolysis process which provides two sets of hydrolysed products containing N-formyl derivatives (J. Org. Chem. 1999, 64, 991–997). Given this unique feature, we conducted hydrolysis studies on the labelled ODN 8 to confirm the identity of the N-hydroxyformamidine structural linkage (Fig. S21). As expected, treatment of the reaction mixture acquired from the photoredox conjugation (containing product 8) with acetate buffer (pH = 4.7) for 60 minutes fully consumed ODN 8 under formation of three new products: N-formyl ODN 14, 3-N-hydroxypyridine derivative 15 and 3- N-formyl-N-hydroxypyridine derivative 16.
The three products 14, 15, and 16 were characterized by HRMS (Fig. S22 and S23).

Importantly, a control experiment where oligonucleotide 7 was subjected to the same procedure (photoredox and hydrolysis) did not result in formation of any of the hydrolysis products according to scans of calculated exact masses with error ranges of up to 100 ppm. Together, these results are consistent with the presence of a N-hydroxyformamidine linkage in the photoredox N<sub>6</sub>mdA product.
Additional evidence for the N-hydroxyformamidine linkage are provided by reactivity studies using hydrazine as nucleophile instead of water (Fig. S24).

**Fig. S24.** Reaction of the formed ‘on-DNA’ N-hydroxyformamidine with hydrazine to form the N-NH₂ formamidine product 13 during pull-down experiments further confirms its identity.

Treatment of immobilised DNA fragment 12 with 10% hydrazine aqueous solution for 5 minutes delivered N-NH₂ formamide ODN 13 along with small amount of 7 (due to the hydrolysis of 13) as detected by LCMS at the end of the pull-down procedure described in Figure 4 of the main text (see also Fig. S30). The formation of the hydrazine product 13 upon treatment of the immobilised product 12 is a further clear indication of the identity of the N-hydroxyformamidine moiety.

Another indication of the presence of the N-hydroxyformamidine moiety is the detection of Ni(II) and Zn(II) adducts of product 8 and the corresponding click product 10 as confirmed by HRMS and isotopic pattern studies (Fig S25, see also Fig. S17).

**Fig. S25.** Formation of Ni(II) and Zn(II) complexes with the ‘on-DNA’ N-hydroxyformamidine moiety that acts as a good bidentate for these metals.

Interestingly, Ni(II) and Zn(II) adducts are only visible for the oligonucleotides that contain the N-hydroxyformamidine moiety (8 and 10). The formation of stable complexes of the generated N-hydroxyformamidines with Ni(II) and Zn(II) is in accordance with previous reports describing these moieties as good bidentate ligands (*Eur. J. Inorg. Chem.* 2004, 1740–1752; *Eur. J. Inorg. Chem.* 2016, 177–185).
Reactions and LC-MS traces for sequences 5b, 5c, 5d and 5e

DNA 24mer 5b sequence (self-complementary):
ATGGCACGTAATGT [N^mdA] CGTGCCAT
DNA 41mer 5c sequence:
ATCGTACTAG [N^mdA] CTCAACGTTAGGGTGTCGTCGTCGCG
DNA 49mer 5d sequence:
5′-CTCAGACGTAAGCTGATGCTAGGATATCGATCGATCG[mdA]TCGTAGCTAAC-3′

[Images of chemical structures and reactions]

10 μM, m/z = 2160.79

12% yield
RNA 13mer 5e sequence:

5'-CUUGACG[m^6A]CUAG-3'

2 M quinuclidine 3
0.1 M 3-nitropyridine 1b
1.1 mM RuPhen3Cl2
H2O-MeCN (9:1), 60 W CFL
10 mins

CUUGACG[N^6mdA]CUAG, 5e
100 μM, m-3/3 = 1378.20

CTTGACG[N^6mdA-PX-N]CTAG
5% yield, m-5/3 = 1468.53
Optimization of ‘click’ Huisgen cycloaddition on alkyne-functionalized N⁶mdA ODN

Having demonstrated that several 3-nitropyridine alkyne derivatives are compatible with our N⁶mdA selective photoredox functionalisation, we next evaluated and optimised the reaction conditions for the ‘click’ Huisgen cycloaddition of azide-PEG₃-biotin 9 into various alkyne-functionalized N⁶mdA oligonucleotides. The selective incorporation of a biotin moiety into N⁶mdA residues is fundamental for the next enrichment studies, which rely on the immobilisation of the N⁶mdA DNA fragments into streptavidin-coated magnetic beads.

Table S2. Conditions and yields for the Huisgen cycloaddition of alkyne-functionalized N⁶mdA ODN with azide-PEG₃-biotin 10. THTPA: Tris(benzyltriazolylmethyl)amine, TCEP: tris(2-carboxyethyl)phosphine, Na-asc.: sodium ascorbate.

| 3-nitropyridine der. | [c] | photoredox conditions | [N⁶mdA-P][X] | ‘click’ conditions | yield | [N⁶mdA-PX][B] | yield |
|---------------------|-----|-----------------------|--------------|-------------------|-------|--------------|-------|
|                     |     | [m/z [M-3H]⁺]         |              |                   |       | [m/z [M-3H]⁺] |       |
| CTTGACGLN⁶mdACTAG    | 5,  (100 μM) | 2 M quinuclidine 3 3-nitropyridine der. | H₂O–MeCN (9:1), 15/60 W CFL 5-60 mins | 3.5 % (1420) | 0.04 M 1 h, 15 W CFL | 2 mM 10 0.2 mM CuSO₄ 1 mM THPTA 0.8 mM TCEP r.t., 1 h | not detected (1568) |
| CTTGACGLN⁶mdA-PXCTAG | (10-15 μM) | 2 M quinuclidine 3 3-nitropyridine der. | H₂O–MeCN (9:1), 15/60 W CFL 5-60 mins | 3.5 % (1420) | 0.04 M 1 h, 15 W CFL | 2 mM 10 0.2 mM CuBr 1 mM THPTA r.t., 1 h | not detected (1568) |
| CTTGACGLN⁶mdA-PX-BCTAG | 2 M quinuclidine 3 3-nitropyridine der. | H₂O–MeCN (9:1), 15/60 W CFL 5-60 mins | 3.5 % (1420) | 0.04 M 1 h, 15 W CFL | 0.04 M | 2 mM 10 0.2 mM CuSO₄ 1 mM THPTA 0.8 mM Na-asc. r.t., 1 h | 23 % (1568) |
| CTTGACGLN⁶mdA-PX-BCTAG | 2 M quinuclidine 3 3-nitropyridine der. | H₂O–MeCN (9:1), 15/60 W CFL 5-60 mins | 3.5 % (1420) | 0.04 M 1 h, 15 W CFL | 0.04 M | 2 mM 10 0.2 mM CuSO₄ 1 M quinuclidine 0.8 mM Na-asc. r.t., 1 h | 24 % (1568) |
The results showed that the alkyne substrate, copper ligand, reductant and time are key parameters for the successful outcome of the reaction. To our surprise, quinuclidine proved to be fundamental as copper ligand compare to well-established water-soluble ligands such as Tris((1-benzyl-4-triazolyl)methyl)amine (TBTA) and 3-[tris(3-hydroxypropyltriazolylmethyl)amine] (THPTA). Sodium ascorbate (Na-asc) was superior to tris(2-carboxyethyl)phosphine (TCEP) as reducing agent and 30 minutes was found to be the best time in term of yield.
LCMS traces of functionalization of N<sup>6</sup>mdA ODN 5 with alkyne-derived 3-nitropyridines and subsequent Huisgen cycloaddition

This is a collection of LC traces of the selective photoredox reactions on N<sup>6</sup>mdA containing ODN 5 and subsequent Huisgen cycloaddition described in Table S2 using different 3-nitropyridine alkyne derivatives (probes). For each probe, the first two chromatograms are the MS and UV traces of the Huisgen cycloaddition using PEG<sub>3</sub> biotin-derived azide 9 on alkyne-functionalized N<sup>6</sup>mdA oligonucleotides (Step 2). The third and the fourth chromatograms represents respectively the MS and UV-trace of the selective photoredox reaction on N<sup>6</sup>mdA containing ODN 5 (Step 1). Finally, the last trace is the MS spectra of the new product peak observed in the Huisgen cycloaddition. The disappearance of the 3-nitropyridine alkyne derivatives [N<sup>6</sup>mdA-PX] obtained after the photoredox conjugation in favour to the new biotin-labelled oligonucleotides [N<sup>6</sup>mdA-PX-B] is a clear evidence for the overall selective biotinylation at N<sup>6</sup>mdA residues.
Fig. S26. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with N-(3-(5-nitropyridin-2-yl)phenyl)hex-5-ynamide on N₆mdA ODN 5 (bottom; base peak MS chromatogram and UV₂₆₀ chromatogram) and after treatment of the resulting mixture for biotinylation with the optimized Huisgen cycloaddition conditions (top; base peak MS chromatogram and UV₂₆₀ chromatogram). The MS shows the extracted mass spectrum of the [N₆mdA-PX-B] peak.
Fig. S27. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with 5-nitro-N-(pent-4-yn-1-yl)picolinamide on N6mdA ODN 5 (bottom; base peak MS chromatogram and UV260 chromatogram) and after treatment of the resulting mixture for biotinylation with the optimized Huisgen cycloaddition conditions (top; base peak MS chromatogram and UV260 chromatogram). The MS shows the extracted mass spectrum of the [N6mdA-PX-B] peak.
Fig. S28. LCMS traces of the reaction mixtures after applying the photoredox functionalization conditions with N-(5-nitropyridin-3-yl)hex-5-ynamide on (bottom; base peak MS chromatogram and UV<sub>260</sub> chromatogram) and after treatment of the resulting mixture for biotinylation with the optimized Huisgen cycloaddition conditions (top; base peak MS chromatogram and UV<sub>260</sub> chromatogram). The MS shows the extracted mass spectrum of the [N<sup>6</sup>mdA-PX-B] (10) peak.
**LCMS monitoring of 12/13nt ssDNA enrichment experiments**

In order to demonstrate the high selectivity of the \(N^6\)mdA functionalisation reaction, we devised an enrichment experiment, consisting of immobilising \(N^6\)mdA-containing ssDNA after biotinylation in the presence of a different unmethylated sequence and washing off unfunctionalised strands. Selective nucleophile-mediated cleavage of the N-hydroxy-formamidine using an aqueous hydrazine solution afforded an enrichment of >50:1 of the initially methylated ssDNA sequence (Fig. S29).

**Fig. S29.** Detailed procedure of the developed \(N^6\)mdA-specific enrichment procedure with different checkpoints for the LCMS-based analysis of the outcome. After treatment with streptavidin-coated magnetic beads, LCMS 1 of the supernatant indicates full removal of 10 from the mixture. LCMS 2 of the first washing mixture shows the three non-biotinylated species 12, 5 and 7. After the first incubation with 0.1 M NaOH, residual 12 and 5 were detected (LCMS 3). Elution with 10% hydrazine in \(H_2O\) releases the selective cleavage product 13 with demethylated 7 and only traces of the other sequence 12.
To control for sequence effects, we run the same experiment with the N⁶mdA residue being in the other ssDNA sequence (Fig. S30). We obtained an enrichment of >30:1 for the N⁶mdA-containing ssDNA sequence, confirming that the enrichment was N⁶mdA-specific.

Fig. S30. Detailed procedure of the control of the N⁶mdA-specific enrichment procedure with an inverted set of ssDNA sequences. After treatment with streptavidin-coated magnetic beads, LCMS 1 of the supernatant indicates full removal of [N⁶-(NHFXB)-dA] from the mixture. LCMS 2 of the first washing mixture shows the three non-biotinylated species 7, [N⁶mdA] and low amounts of 11. After the first incubation with 0.1 M NaOH, residual 12 and 5 were detected (LCMS 3). Elution with 10% hydrazine in H₂O releases the selective cleavage product [R-A] with demethylated 11 and only traces of the other sequence 7.
Enrichment studies of 99nt ssDNA

To test if the developed N⁶mdA-specific DNA enrichment protocol can also be applied on longer ssDNA strands, and if enriched DNA can be amplified, we applied it on a set of two 99nt ssDNA strands (with an N⁶mdA residue being in one sequence for (a) and in the other for (b)) and quantified both sequences by qPCR after enrichment (Fig. S31). Obtained enrichment factors of 6:1 for the respective methylated sequences demonstrated the applicability of the enrichment procedure on 99nt DNA strands.

Fig. S31. Top: Scheme of the enrichment experiments with a set of two synthetic 99nt ssDNA strands with either one (a) or the other (b) being methylated. Bottom: outcome for the enrichment experiments (fold enrichment of amplifiable N⁶mdA-containing strand) as determined by qPCR. Mean values of two independent experiments, error bars indicate standard deviation.
We also added excess salmon sperm DNA in an additional set of experiments to show that the presence of additional DNA (to reach an overall theoretical N\textsuperscript{6}mdA/A ratio of 1:383 (0.26%)) does not interfere with the N\textsuperscript{6}mdA-selective chemistry (Fig. S32). Enrichment factors of 10:1 showed that excess background DNA does not interfere with the process.

**Fig. S32.** Top: Scheme of the enrichment experiments with a set of two synthetic 99nt ssDNA strands with either one or the other being methylated in the presence of salmon sperm DNA. Bottom: outcome for the enrichment experiments (fold enrichment of amplifiable N\textsuperscript{6}mdA-containing strand) as determined by qPCR. For ii: mean value of two independent experiments, error bars indicate standard deviation. The calculated N\textsuperscript{6}mdA/A ratio is 1:383 (0.26%).
Enrichment studies of 99bp dsDNA

To test the developed N$_6$mdA-specific enrichment protocol on dsDNA, we applied it on a set of two 99bp dsDNA strands and quantified the outcome by qPCR (Fig. S33). Enrichment factors of 4:1 (iii, for one N$_6$mdA) and 9:1 (iv, for two N$_6$mdA) demonstrated the compatibility with dsDNA as well as a positive cumulative effect in the enrichment factors for higher N$_6$mdA densities.

Fig. S33. Top: Scheme of the enrichment procedure of a synthetic adenine N$_6$-methylated 99bp dsDNA strand from a mixture with a different synthetic nonmethylated sequence. Bottom: outcome for the enrichment experiments (fold enrichment of amplifiable N$_6$mdA-containing dsDNA sequence) as determined by qPCR. For iii: mean value of two independent experiments (where error bars present), error bars indicate standard deviation.
We also added excess salmon sperm DNA in an additional set of experiments to show that the presence of additional DNA (to reach an overall theoretical N⁶mdA/A ratio of 1:383 (0.26%)) does not interfere with the N⁶mdA-selective chemistry (Fig. S32). Enrichment factors of 10:1 showed that excess background DNA does not interfere with the process.

Fig. S34. Top: Scheme of the enrichment experiments with a set of two synthetic 99nt dsDNA strands with either one or the other being methylated in the presence of salmon sperm DNA. Bottom: outcome for the enrichment experiments (fold enrichment of amplifiable N⁶mdA-containing strand) as determined by qPCR. Mean values of two independent experiments, error bars indicate standard deviation. The calculated N⁶mdA/A ratio is 1:3433 (0.03%) for the dsDNA fragment containing one N⁶mdA (v, blue) and 1:1716.5 (0.06%) for the dsDNA fragment containing two N⁶mdA (vi, green).
Synthesis of compounds and oligonucleotides

Synthesis and characterization of derivatives of quinuclidine and 3-nitropyridine

General procedure J: Suzuki coupling of aryl boronic acids to chloro- or bromo-3-nitropyridines
The appropriate chloro- or bromo-3-nitropyridine and arylboronic acid were dissolved in a 1:1 (v/v) mixture of THF and 20 % (wt) Na₂CO₃ in H₂O under an atmosphere of argon. Tetrakis(triphenylphosphine)palladium(0) (10-20 mol%) was added and the mixture was refluxed for 2 h. After dilution with H₂O the mixture was extracted with CH₂Cl₂ (3x). The combined organic layers were dried (MgSO₄) and the solvents evaporated. Crude products were purified by flash column chromatography.

General procedure K: Amide couplings of aromatic amines or carboxylic acids with 5-hexynoic acid or propargylamine/4-pentyne-1-amine
The appropriate carboxylic acid (1 equiv.), amine (1 equiv.) and Et₃N (1 equiv.) were dissolved in dry DMF under an atmosphere of argon. The mixture was cooled to 0 ºC and pyBOP (1 equiv.) was added. The mixture was stirred overnight, allowing it to slowly reach r.t. It was then diluted with H₂O and extracted with EtOAc. The combined organic layers were dried (MgSO₄) and the solvents evaporated. Crude products were purified by flash column chromatography.

2-(quinuclidin-3-yl)propan-2-ol

Methyl-3-quinuclidinecarboxylate hydrochloride was converted to its free base by dissolution in sat. aq. K₂CO₃ and extraction with CHCl₃.

Methyl-3-quinuclidinecarboxylate (99 mg, 0.59 mmol) was dissolved in 5 ml dry Et₂O under an atmosphere of argon and cooled to -78 ºC. MeLi (1.6 M in Et₂O, 1.5 ml, 2.36 mmol) was added slowly and the mixture was stirred at -78 ºC for 3 h. The reaction was quenched with sat. aq. NH₄Cl (0.2 ml), and sat. aq. K₂CO₃ (5 ml) was subsequently added. This mixture was extracted with Et₂O, the combined organic layers were dried with MgSO₄, and the solvents were evaporated. The crude product was purified by flash column chromatography (0-10% MeOH in CH₂Cl₂ with 0.5 % Et₃N). The purified product was extracted from sat. aq. K₂CO₃ (5 ml) with Et₂O to afford free base of 2-(quinuclidin-3-yl)propan-2-ol (30 mg, 0.18 mmol, 31%).

¹H NMR (400 MHz, Methanol-d₄) δ (ppm) 3.01 – 2.66 (m, 6H), 2.20 – 2.09 (m, 1H), 1.99 (s, 1H), 1.73 – 1.53 (m, 3H), 1.44 – 1.32 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H). ¹³C NMR (101 MHz, Methanol-d₄) δ 72.9, 50.5, 48.2, 47.4, 46.7, 30.5, 28.8, 28.6, 23.5, 23.3. HMRS-ESI (m/z): found [M+H]⁺ 170.1537 C₁₀H₂₀NO requires 170.1545
5-nitro-2-phenylpyridine

Synthesised according to General Procedure J from 2-bromo-5-nitropyridine (203 mg, 1 mmol) and phenylboronic acid (183 mg, 1.5 mmol) to afford product as a white solid (112 mg, 0.56 mmol, 56%).

$^1$H NMR (400 MHz, CDCl$_3$) δ (ppm) 9.50 (dd, $J$ = 2.7, 0.6 Hz, 1H), 8.53 (dd, $J$ = 8.8, 2.7 Hz, 1H), 8.13 – 8.06 (m, 2H), 7.92 (dd, $J$ = 8.8, 0.6 Hz, 1H), 7.57 – 7.51 (m, 3H); $^{13}$C NMR (101 MHz, CDCl$_3$) δ (ppm) 162.6, 145.4, 143.0, 137.2, 132.1, 131.0, 129.3, 127.8, 120.2;HMRS-ESI (m/z): found [M+H]$^+$ 201.0660, C$_{11}$H$_9$N$_2$O$_2$ requires 201.0659.

3-nitro-4-phenylpyridine

Synthesised according to General Procedure J from 4-chloro-3-nitropyridine (1.00 g, 6.3 mmol) and phenylboronic acid (0.90 g, 7.4 mmol) to afford product as a pale yellow solid (0.65 g, 3.3 mmol, 52%).

$^1$H NMR (400 MHz, CDCl$_3$) δ (ppm) 9.08 (s, 1H), 8.81 (d, $J$ = 5.1 Hz, 1H), 7.50 – 7.46 (m, 3H), 7.42 (d, $J$ = 5.0 Hz, 1H), 7.37 – 7.33 (m, 2H). $^{13}$C NMR (101 MHz, CDCl$_3$) δ (ppm) 152.8, 145.7, 145.3, 144.1, 134.56 129.8, 129.2, 127.7, 125.9. HMRS-ESI (m/z): found [M+H]$^+$ 201.0656, C$_{11}$H$_9$N$_2$O$_2$ requires 201.0659.
(3-(hex-5-ynamido)phenyl)boronic acid

Synthesised according to General Procedure K from 3-aminophenylboronic acid monohydrate (310 mg, 2.0 mmol) and 5-hexynoic acid (0.22 ml, 2.0 mmol) to afford the product as a white solid containing 15mol% tripyrrolidinophosphine oxide (344 mg, 1.3 mmol, 67%) which was used without further purification for subsequent suzuki couplings.

\[ \text{H NMR (400 MHz, Methanol-} d_4 \text{)} \delta (ppm) 7.84 – 7.72 (m, 1H), 7.61 (d, J = 7.3 Hz, 1H), 7.51 – 7.22 (m, 2H), 3.14 (td, J = 6.6, 3.7 Hz, 2H), 2.50 (t, J = 7.5 Hz, 2H), 2.32 – 2.23 (m, 1H), 1.88 (p, J = 7.3 Hz, 2H). \]

\[ \text{C NMR (101 MHz, Methanol-} d_4 \text{)} \delta (ppm) 173.8, 139.2, 130.2, 129.1, 126.2, 122.6, 84.1, 70.3, 36.6, 25.7, 18.7 \text{ (one quaternary aromatic C not detected).} \]

\[ \text{HMRS-ESI (m/z): found [M+H]^{+} 232.1135, C}_{12}\text{H}_{15}\text{BNO}_{3} \text{ requires } 232.1140. \]

N-(3-(5-nitropyridin-2-yl)phenyl)hex-5-ynamide

Synthesised according to General Procedure J from 2-bromo-5-nitropyridine (102 mg, 0.5 mmol) and (3-(hex-5-ynamido)phenyl)boronic acid (116 mg, 0.5 mmol) to afford the product as a pale yellow solid (52 mg, 0.17 mmol, 34%).

\[ \text{H NMR (400 MHz, CDCl}_3 \text{)} \delta (ppm) 9.48 (dd, J = 2.7, 0.6 Hz, 1H), 8.53 (dd, J = 8.8, 2.7 Hz, 1H), 8.35 (app s, 1H), 7.94 (dd, J = 8.8, 0.6 Hz, 1H), 7.83 (app d, J = 8.0 Hz, 1H), 7.68 (app d, J = 8.0 Hz, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.42 – 7.32 (bs, 1H), 2.57 (t, J = 7.3 Hz, 2H), 2.36 (td, J = 6.8, 2.6 Hz, 2H), 2.04 (t, J = 2.6 Hz, 1H), 1.99 (qnt, J = 7.1 Hz, 2H); \]

\[ \text{C NMR (101 MHz, CDCl}_3 \text{)} \delta (ppm) 170.9, 162.0, 145.3, 143.2, 138.9, 138.0, 132.1, 130.0, 123.6, 122.1, 120.4, 119.0, 83.5, 70.0, 36.1, 24.0, 17.9; \]

\[ \text{HMRS-ESI (m/z): found [M+H]^{+} 310.1188, C}_{17}\text{H}_{18}\text{N}_{3}\text{O}_{3} \text{ requires } 310.1186. \]
N-(3-(5-nitropyridin-3-yl)phenyl)hex-5-ynamide

Synthesised according to General Procedure J from 3-bromo-5-nitropyridine (51 mg, 0.25 mmol) and (3-(hex-5-ynamido)phenyl)boronic acid (53 mg, 0.23 mmol) to afford the product as a pale orange solid (46 mg, 0.15 mmol, 65%).

\(^1^H\) NMR (400 MHz, CDCl\(_3\)) \(\delta\) (ppm) 9.42 (d, \(J = 2.4\) Hz, 1H), 9.13 (d, \(J = 2.0\) Hz, 1H), 8.66 (app. t, \(J = 2.3\) Hz, 1H), 8.01 (app. s, 1H), 7.52 – 7.42 (m, 3H), 7.37 (d, \(J = 7.0\) Hz, 1H), 2.58 (t, \(J = 7.3\) Hz, 2H), 2.36 (td, \(J = 6.7, 2.6\) Hz, 2H), 2.03 (t, \(J = 2.6\) Hz, 1H), 1.97 (app. q, \(J = 7.0\) Hz, 2H). \(^{13}\)C NMR (101 MHz, CDCl\(_3\)) \(\delta\) (ppm) 171.0, 153.2, 144.6, 143.6, 139.1, 137.4, 136.2, 130.3, 129.3, 123.2, 120.5, 118.7, 83.5, 69.7, 36.1, 23.9, 17.9. HMRS-ESI (m/z): found [M+H]\(^+\) 310.1181, C\(_{17}\)H\(_{16}\)N\(_3\)O\(_3\) requires 310.1186.

N-(3-(3-nitropyridin-4-yl)phenyl)hex-5-ynamide

Synthesised according to General Procedure J from 4-chloro-3-nitropyridine (150 mg, 0.95 mmol) and (3-(hex-5-ynamido)phenyl)boronic acid (200 mg, 0.87 mmol) to afford the product as an off-white solid (187 mg, 0.61 mmol, 70%).

\(^1^H\) NMR (400 MHz, CDCl\(_3\)) \(\delta\) (ppm) 9.08 (s, 1H), 8.81 (d, \(J = 5.0\) Hz, 1H), 7.70 (app s, 1H), 7.51 (app d, \(J = 8.4\) Hz, 1H), 7.43 (d, \(J = 5.8\) Hz, 1H), 7.41 (t, \(J = 8.0\) Hz, 1H), 7.36 – 7.31 (bs, 1H), 7.07 (app d, \(J = 7.8\) Hz, 1H), 2.54 (t, \(J = 7.3\) Hz, 2H), 2.34 (td, \(J = 6.8, 2.6\) Hz, 2H), 2.02 (t, \(J = 2.6\) Hz, 1H), 1.96 (qnt, \(J = 7.0\) Hz, 2H); \(^{13}\)C NMR (101 MHz, CDCl\(_3\)) \(\delta\) (ppm) 170.7, 152.9, 145.5, 145.2, 134.5, 129.7, 125.8, 123.4, 120.6, 118.9, 83.3, 69.6, 35.9, 23.7, 17.8; HMRS-ESI (m/z): found [M+H]\(^+\) 310.1189, C\(_{17}\)H\(_{16}\)N\(_3\)O\(_3\) requires 310.1186.
3-(3-nitropyridin-4-yl)benzoic acid

![Chemical structure of 3-(3-nitropyridin-4-yl)benzoic acid]

Synthesised according to General Procedure J from 4-chloro-3-nitropyridine (200 mg, 1.26 mmol) and 3-carboxyphenylboronic acid (231 mg, 1.39 mmol) with extended reaction time (reflux for 20 h) to afford the product as a pale orange solid (162 mg, 0.60 mmol, 47%).

\[ ^1H \text{ NMR (500 MHz, CDCl}_3 \] \( \delta \) (ppm) 9.19 (s, 1H), 8.88 (d, \( J = 5.0 \) Hz, 1H), 8.23 (d, \( J = 7.5 \) Hz, 1H), 8.11 (s, 1H), 7.61 (app. t, \( J = 7.5 \) Hz, 1H), 7.57 (d, \( J = 7.8 \) Hz, 1H), 7.45 (d, \( J = 4.9 \) Hz, 1H).

\[ ^{13}C \text{ NMR (126 MHz, CDCl}_3 \] \( \delta \) 168.9, 153.1, 145.6, 145.1, 143.1, 135.2, 132.7, 131.2, 130.1, 129.4, 129.3, 125.8. \text{ HMRS-ESI (m/z): found [M+H]^+ 245.0551, C}_{12}H_{9}N_2O_4 requires 245.0557.}

3-(3-nitropyridin-4-yl)-N-(pent-4-yn-1-yl)benzamide

![Chemical structure of 3-(3-nitropyridin-4-yl)-N-(pent-4-yn-1-yl)benzamide]

Synthesised according to General Procedure K from 3-(3-nitropyridin-4-yl)benzoic acid (18 mg, 0.074 mmol) and 4-pentyne-1-amine hydrochloride (11 mg, 0.089 mmol) to afford the product as an off-white solid (17 mg, 0.055 mmol, 74%).

\[ ^1H \text{ NMR (500 MHz, CDCl}_3 \] \( \delta \) (ppm) 9.15 (s, 1H), 8.85 (d, \( J = 5.0 \) Hz, 1H), 7.83 (ddd, \( J = 7.7 \), 1.8, 1.1 Hz, 1H), 7.80 (dt, \( J = 1.8 \), 0.9 Hz, 1H), 7.54 (td, \( J = 7.7 \), 0.6 Hz, 1H), 7.46 – 7.41 (m, 2H), 6.47 (app. s, 1H), 3.61 (td, \( J = 6.7 \), 5.8 Hz, 2H), 2.34 (td, \( J = 6.8 \), 2.7 Hz, 2H), 2.03 (t, \( J = 2.7 \) Hz, 1H), 1.88 (app. p, \( J = 6.8 \) Hz, 2H). \[ ^{13}C \text{ NMR (126 MHz, CDCl}_3 \] \( \delta \) 166.8, 153.2, 145.6, 145.3, 143.5, 135.8, 135.4, 130.6, 129.4, 127.7, 126.7, 126.0, 83.76, 69.7, 39.7, 28.0, 16.5. \text{ HMRS-ESI (m/z): found [M+H]^+ 310.1182, C}_{17}H_{16}N_3O_3 requires 310.1186.}
5-nitro-N-(pent-4-yn-1-yl)picolinamide

\[
\text{Synthesised according to General Procedure K from 5-nitropyridine-2-carboxylic acid (141 mg, 0.84 mmol) and 4-pentyne-1-amine hydrochloride (100 mg, 0.84 mmol) to afford the product as an off-white solid (166 mg, 0.71 mmol, 85%).}
\]

\[\text{\textbf{\textsuperscript{1}H NMR (400 MHz, CDCl}_3\text{)} \delta (ppm) 9.37 (d, } J = 2.5 \text{ Hz, 1H), 8.64 (dd, } J = 8.5, 2.3 \text{ Hz, 1H), 8.42 (d, } J = 8.5 \text{ Hz, 1H), 8.16 (app. s, 1H), 3.64 (app. q, } J = 6.6 \text{ Hz, 2H), 2.33 (td, } J = 6.9, 2.6 \text{ Hz, 2H), 2.02 (t, } J = 2.6 \text{ Hz, 1H), 1.90 (app. p, } J = 6.9 \text{ Hz, 2H).} \]

\[\text{\textbf{\textsuperscript{13}C NMR (101 MHz, CDCl}_3\text{)} \delta (ppm) 162.4, 154.2, 145.7, 143.9, 132.9, 123.0, 83.2, 69.6, 39.0, 28.2, 16.3.} \]

\[\text{\textbf{HMRS-ESI (m/z): found [M+H]}^+ 234.0868, C_{11}H_{12}N_{3}O_3 \text{ requires 234.0879.}} \]

\[\text{N-(5-nitropyridin-3-yl)hex-5-ynamide, 1b} \]

\[
\text{Synthesised according to General Procedure K from 3-amino-5-nitropyridine (139 mg, 1.00 mmol) and 5-hexynoic acid (0.11 ml, 1.00 mmol) to afford the product as a pale orange solid (96 mg, 0.41 mmol, 41%).}
\]

\[\text{\textbf{\textsuperscript{1}H NMR (400 MHz, CDCl}_3\text{)} \delta (ppm) 9.16 (d, } J = 2.3 \text{ Hz, 1H), 9.02 (app. t, } J = 2.5 \text{ Hz, 1H), 8.90 (d, } J = 2.3 \text{ Hz, 1H), 7.68 (s, 1H), 2.63 (t, } J = 7.2 \text{ Hz, 2H), 2.36 (td, } J = 6.7, 2.7 \text{ Hz, 2H), 2.04 (t, } J = 2.7 \text{ Hz, 1H), 1.99 (app. p, } J = 7.0 \text{ Hz, 2H).} \]

\[\text{\textbf{\textsuperscript{13}C NMR (101 MHz, CDCl}_3\text{)} \delta (ppm) 171.9, 145.1, 143.2, 137.3, 136.9, 123.2, 83.2, 70.0, 35.9, 23.57, 17.9.} \]

\[\text{\textbf{HMRS-ESI (m/z): found [M+H]}^+ 234.0876, C_{11}H_{12}N_{3}O_3 \text{ requires 234.0879.}} \]
5-nitro-N-(prop-2-yn-1-yl)picolinamide

Synthesised according to General Procedure K from 5-nitropyridine-2-carboxylic acid (141 mg, 0.84 mmol) and propargylamine (54 µl, 0.84 mmol) to afford the product as a pale yellow solid (124 mg, 0.60 mmol, 72 %).

$^1$H NMR (400 MHz, CDCl$_3$) δ (ppm) 9.39 (d, $J = 2.5$ Hz, 1H), 8.65 (dd, $J = 8.6$, 2.5 Hz, 1H), 8.42 (d, $J = 8.6$ Hz, 1H), 8.15 (app. s, 1H), 4.30 (dd, $J = 5.6$, 2.6 Hz, 2H), 2.31 (t, $J = 2.6$ Hz, 1H). $^{13}$C NMR (101 MHz, CDCl$_3$) δ (ppm) 162.0, 153.6, 145.9, 144.0, 132.9, 123.2, 78.8, 72.3, 29.7. HMRS-ESI (m/z): found [M+H]$^+$ 206.0557, C$_9$H$_8$N$_3$O$_3$ requires 206.0566.
Enzymatic synthesis of N\textsuperscript{6}mdA-containing dsDNA

dsDNA was synthesised enzymatically by primer elongation with Vent\textsuperscript{®} DNA Polymerase (NEB) using a non-methylated template (sequences see below), the according reverse primer (sequences see below) and either a set of canonical dNTPs (to synthesise non-methylated dsDNA) or a mixture dCTP, dGTP, N\textsuperscript{6}mdATP and dTTP (to synthesise dsDNA with N\textsuperscript{6}mdA at the indicated positions).

**template 1**
AACGGAAGCAGAACAGAACGAGCAAGACGACAAACACGAAACGAAACGAAACGAAACGAAACGAAACGAAACGAA
CAAGCAACGTTCGTTGCTGCTGCGTGTG

**template 2**
AACGGAAGCAGAACAGAACGAGCAAGACGACAAACACGAAACGAAACGAAACGAAACGAAACGAAACGAAACGAA
CAAGCAACGTTCGTTGCTGCTGCGTGTG

**reverse primer 1**
CAACAGCGAACAGCAACGAA

**reverse primer 2**
CGAACAGCAACAGCAACCGAA

5-10 parallel reactions were run with following optimised concentrations:

| reagent                        | final c/amount |
|-------------------------------|----------------|
| template                      | 0.5 ug         |
| primer                        | 10 \(\mu\)M    |
| Vent\textsuperscript{®} DNA Polymerase (NEB) | 2 U            |
| ThermoPol\textsuperscript{®} Reaction buffer (NEB) | 1X             |
| dATP or N\textsuperscript{6}m-dATP | 2 mM          |
| dCTP                          | 2 mM           |
| dGTP                          | 2 mM           |
| dTTP                          | 2 mM           |
| \(\text{H}_2\text{O}\)         | for a final volume of 20 \(\mu\)l |

The reactions were run using the following optimised temperature cycle:

| Step                | Time | Temperature |
|---------------------|------|-------------|
| melting/denaturing  | 30 sec | 95 °C      |
| primer annealing    | 1 min | 60 °C      |
| polymerisation      | 10 min | 72 °C      |
| storage             | inf.  | 4 °C       |

Upon reaction, the parallel PCR reactions were combined and the PCR products purified with the GeneJet PCR purification kit (Thermo Scientific) according to the manufacturer’s protocol (without the use of iPrOH). The products were analysed by automated gel electrophoresis (Tapestation) and LCMS to confirm the identity of the synthesised strands.
NMR spectra of synthesised compounds

\[
\begin{align*}
\text{NMR spectrum}\end{align*}
\]
